Sign Up to like & get
recommendations!
1
Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3738-x
Abstract: PurposeRegorafenib is an oral multi-kinase inhibitor that offers an OS benefit to patients with mCRC refractory to standard therapy (Grothey et al., in Lancet 381:303–312, 2013), but comes with potential significant toxicities including grade 3…
read more here.
Keywords:
foot skin;
skin reaction;
hfsr;
severity ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2019.1689122
Abstract: ABSTRACT Introduction: Sorafenib is a multitargeted tyrosine kinase inhibitor, which has been mainly used in the treatment of advanced hepatocellular carcinoma and renal cancer. However, hand-foot skin reaction (HFSR), as one of the most common…
read more here.
Keywords:
foot skin;
mechanism;
hfsr;
sorafenib ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.3551
Abstract: 3551Background: Cutaneous toxicity is a known adverse effect of multikinase inhibitors and has been associated with clinical outcomes (Granito 2016). In the phase 3 CORRECT trial (NCT01103323), the multikinase inhibitor regorafenib significantly improved overall survival…
read more here.
Keywords:
hfsr;
phase correct;
hand foot;
regorafenib ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Cancer Management and Research"
DOI: 10.2147/cmar.s285002
Abstract: Background Multi-kinase inhibitors (MKIs) treatment plays an important role in cancer therapy, but still suffers from a high incidence of hand–foot skin reaction (HFSR), leading to MKIs dose modification or termination. Thus, there is a…
read more here.
Keywords:
hand foot;
hfsr;
treatment;
multi ... See more keywords